Building on momentum of the Cobenfy breakthrough and major pharma investments, such as Johnson & Johnson’s acquisition of Intra-Cellular, 2025 witnessed continued momentum in partnerships and clinical progress. Yet, with persistently high failure rates driven by high placebo responses, the lack of objective biomarkers, and poor translatability, deeper collaboration and more advanced solutions are urgently needed to truly accelerate the development of transformative mental health treatments.
In September 2025, organizations partnering with the 8th Neuropsychiatric Drug Development Summit connected with decision-makers actively investing in innovative discovery technologies, preclinical and clinical CROs, EEG analysis tools and more. Across three days of targeted discussions, our 2025 partners had the opportunity to elevate their brand, forge key partnerships, and position their solutions at the forefront of the next wave of neuropsychiatry breakthroughs.
2025 Partners
What Are Neuropsychiatric Drug Developers Seeking from New Partners?
Enhanced Tools for Generating & Analyzing Good Quality EEG Data
Preclinical Assays that can Predictively Model Human-Relevant Psychiatric Disease Phenotypes
Navigating Mood Disorder Heterogeneity with State of the Art Technologies to Detect Specific Symptoms Earlier
Reliable Monitoring Technologies to Objectively Measure Mood & Behavioural Symptoms
Support with Placebo-Controlled Studies to Generate High-Quality Clinical Data & Streamline Site Selection & Recruitment
How Can You Get Involved?
Conference Chairing
Hosted Private Lunches
Focus Day Hosting
Panel Discussion Moderating
Additional Branding Opportunities
Who Did You Meet?
